Predictable site-level scaling.
NeuralPoint is designed for scalable clinical adoption through low-barrier device placement and recurring AI software licensing - with platform refinement through structured data accumulation.
Device-enabled recurring AI platform.
A pragmatic model aligned to how sleep diagnostics are delivered today - designed for durable, growing revenue as utilization scales.
Diagnostic indexing
Per-patient biomarker scoring to support evaluation, stratification, and care planning. High consistent site revenue streams.
Recurring AI licensing
EMGNet™ generates ongoing software licensing revenue per test, depending on utilization and integration scope.
Strategic partnerships
Clinical collaborations supporting validation studies, discovery, and expansion into adjacent indications - building digital cloud-based platform value while generating structured data.
Commercial Roadmap.
A phased deployment strategy from academic validation to specialty scaling.
Phase 1: Academic
2–3 sites for validation, refinement, and workflow integration. Building the structured evidence base and clinical relationships that underpin scalable deployment.
- BDD/PCCP/510K/De Novo
- KOL partnerships
Phase 2: Integrated systems
Expanding into integrated health systems with established workflows and large patient populations.
- Workflow automation
- Enterprise SaaS rollout
Phase 3: Specialty scaling
Repeatable site-level deployment across sleep medicine, otolaryngology, and hospital setting. Platform refinement and expanding utilization drive growing ARR per site.
- Global distribution
Primary initial customer profile
Academic sleep centers (Phase 1) - validation partners who become early commercial customers, establishing the clinical and commercial foundation for broader deployment.
*All pricing, reimbursement, and commercial assumptions are placeholders for planning and will be finalized with clinical and payer inputs.
Regulatory Roadmap.
FDA Strategy to Achieve Breakthrough Designation & Clearance
Investment Thesis & Platform
INVESTMENT THESIS
- Regulatory clarity is the primary valuation driver
- Early FDA alignment eliminates binary risk
- Breakthrough pathway enables accelerated growth
PLATFORM & PATHWAY
- EMG-based diagnostic platform (AIMS-Dx)
- Indication: Obstructive Sleep Apnea
- Pathway: De Novo / 510(k)
- Breakthrough Designation candidate
FDA Engagement Strategy & Timeline
PRE-SUBMISSION STRATEGY
- Align on classification, endpoints, and study design
- De-risk before pivotal capital deployment
BREAKTHROUGH PATHWAY
- Based on unmet clinical need
- Accelerated FDA interaction and review
EXECUTION TIMELINE
- 0–6M Strategy + Pre-Sub
- 6–12M Breakthrough decision + protocol
- 12–18M Pivotal study + submission
- 18–24M Clearance + reimbursement
Value Creation & Use of Capital
VALUE MILESTONES
- Pre-Sub -> validated regulatory path
- Breakthrough -> valuation step-up
- Pivotal study -> institutional entry
- FDA clearance -> commercialization
USE OF CAPITAL
- FDA strategy and Pre-Sub execution
- Breakthrough submission
- Clinical readiness
- Regulatory infrastructure
INVESTOR OUTCOME
- Reduced risk and capital efficiency
- Clear Series A inflection points